GlassScriptPhysician profile
Swathi Parvataneni
NPI 1881079028
$4,386.12
in general payments reported to CMS, 2019-2025
18 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what 89% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $65.18 · 2021: $314 · 2022: $708 · 2023: $617 · 2024: $948 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,932.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $755.86 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $627.26 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $550.36 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $467.29 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $411.47 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $380.63 | 2021-2025 | Caplyta |
| Alkermes, INC. | $290.63 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $252.21 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Braeburn INC. | $147.26 | 2024-2025 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $134.13 | 2021-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $112.54 | 2021-2022 | |
| Livanova USA, INC. | $73.84 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| E.R. Squibb & Sons, L.L.C. | $65.80 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $35.05 | 2022-2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $24.72 | 2024 | Fanapt |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioxcel Therapeutics, INC. | $24.33 | 2024 | Igalmi |
| Ironshore Pharmaceuticals INC. | $17.53 | 2024 | |
| Allergan, INC. | $15.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swathi Parvataneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.